Preliminary financial data of Lietuvos Energija for 5 months of 2018
Lietuvos Energija, UAB, (hereinafter – the Company or Lietuvos Energija) identification code 301844044, registered office placed at Žvejų str. 14, Vilnius, Republic of Lithuania. The total nominal value of issued bonds 300 000 000 EUR; ISIN code XS1646530565.
Preliminary financial data of Lietuvos Energija for 5 months of 2018:
| May | |||
| 2018 | 2017 | Change | |
| Revenue | EUR 86.4 million | EUR 76.1 million | 13.5 % |
| Adjusted EBITDA* | EUR 17.2 million | EUR 15.8 million | 8.9 % |
| January - May | |||
| 2018 | 2017 | Change | |
| Revenue | EUR 534.2 million | EUR 467.6 million | 14.2 % |
| Adjusted EBITDA* | EUR 113.5 million | EUR 104.2 million | 8.9 % |
In January-May 2018, Lietuvos Energija generated revenue of EUR 534.2 million, which is 14.2% more compared to a respective period of 2017 (EUR 467.6 million). The Group's revenue has grown due to higher demand for electricity and gas, with lower average air temperature compared to the same period last year and the price change in the gas and electricity markets.
The adjusted EBITDA indicator of the Group was equal to EUR 113.5 million, i.e. 8.9% more compared to a respective period of 2017 (EUR 104.2 million). The growth of the indicator was driven by a better result from the distribution of electricity and gas due to more efficient operation and increased investment in renewal and modernization of distribution networks.
*The Company’s preliminary (2018) and actual (2017) result of adjusted EBITDA is presented after the adjustments made by the management by eliminating the impact of one-off factors. These adjustments are intended to disclose the results of the Company’s operating activity without taking into consideration atypical, one-off factors or factors that have no direct relation with the current period of operations. All adjustments made by the management are disclosed in the Company’s interim and annual reports.
More information: Laura Šebekienė, Head of Corporate Communications of Lietuvos Energija +370 633 99940, laura.sebekiene@le.lt
© 2018 GlobeNewswire, Inc. All Rights Reserved.
FSD Pharma (Nasdaq: HUGE) Receives U.S. FDA Approval to design a Phase 2a Clinical Trial to Treat Patients with Suspected or Confirmed COVID-19 Diagnosis
